Background: The expression levels of excision repair cross-complementation group 1 (ERCC1), replication protein A (RPA) and xeroderma pigmentosum group F (XPF) nucleotide excision repair proteins may be important in the response to platin-based therapy in lung cancer patients. It is not known whether ERCC1, RPA and XPF expression levels differ between ever smokers (ES) and never smokers (NS).
introduction About 90% of lung cancer deaths are caused by tobacco smoking [1] . Adenocarcinoma (AC) is the most common type of lung cancer and the least strongly associated with smoking. Over the last several decades, its incidence has increased in relation to other histological types. Although cigarette smoking is the main risk factor for lung cancer, lung cancer in never smokers (NS) ranks as the seventh most common cause of cancer death worldwide, ahead of cancer of the cervix, pancreas and prostate [1] .
Exposure to tobacco smoke carcinogens is directly responsible for gene alterations seen in lung cancer. Striking differences between ever smokers (ES) and NS have been found in the mutation rate in the three major genes EGFR, KRAS and TP53 that are involved in the pathogenesis of lung cancers. These differences suggest that lung cancer arises via different molecular mechanisms in NS compared with ES. The TP53 mutational signature (ratio of transitions, transversions and deletions) and the mutational spectrum (distribution of mutations along the gene) are distinct in lung cancers in ES and NS [2] . Mutations in EGFR have emerged as a frequent molecular alteration in lung cancer in NS [3, 4] . Furthermore, EGFR and KRAS mutations exhibit a mutually exclusive distribution [5] . Epigenetic changes such as DNA methylation differ in NS from those described in ES and more specifically in p16, hMLH1 and hMSH2 [6, 7] . Also, chromosomal aberrations in lung cancer have been described as possibly different in NS and in ES [8] .
Platinum-based chemotherapy has been used to treat a wide variety of solid tumours including lung, head and neck, ovarian, cervical and testicular cancer for over three decades [9] . Many patients eventually relapse following treatment and become refractory to these anticancer agents [10] . Chemotherapy failure is mainly due to drug resistance in tumour cells. Recent capacity may have a major impact on the onset of drug resistance [11] . The cytotoxic effects of platin-based combinations depend on the formation of platinum-DNA adducts, which cause inter-and intrastrand cross-linking that triggers a series of intracellular events that ultimately result in cell death [10, 11] . DNA adducts are processed and repaired by the nucleotide excision repair (NER) pathway, a complex network of at least 25 polypeptides [12] . The NER pathway contains several steps, including lesion recognition, opening of the double DNA helix around the damage, excision of the DNA strand carrying the platinum adduct and polymerization of a new DNA strand followed by its ligation. Excision repair cross-complementation group 1 (ERCC1) is a component of the NER pathway, which is essential for the repair of platinum-DNA adducts and is associated with cellular resistance to platinum compounds [13] [14] [15] . ERCC1 is one of the ratelimiting enzymes in the NER complex, together with its obligate partner, the xeroderma pigmentosum group F (XPF) protein [16] . The ERCC1-XPF heterodimeric protein complex is responsible for the incision that cleaves on the 5# side of the DNA strand lesion. In addition, the ERCC1-XPF complex must interact with the replication protein A (RPA) for the DNA binding step. In fact, RPA plays a crucial role in damage recognition and in the positioning of the incision steps of excision repair through cooperative DNA binding with ERCC1-XPF such that the nuclease incises only the damaged strand [12, 17] . The ERCC1-XPF structure-specific nuclease also plays a role in the homologous recombination repair of interstrand cross-links [18] . We reported in the IALT-Bio study that patients with completely resected non-small-cell lung cancer (NSCLC) and ERCC1-negative tumours benefited from adjuvant cisplatinbased chemotherapy, whereas patients with ERCC1-positive tumours did not [15] . Other reports confirmed that ERCC1 expression was correlated with a better prognosis in the observation group [19, 20] .
We had no information on the smoking status of the patients included in the IALT-Bio study. Therefore, we used samples from another cohort of patients with lung AC who had undergone curative surgery and for whom the smoking status was precisely established. Here, we report results on the expression of ERCC1 and its partners XPF and RPA in ES and NS in lung AC.
patients and methods

clinical data
Using a single institution clinical database (Institut Mutualiste Montsouris, Paris, France), 217 patients with lung AC who had undergone curative surgery from January 1995 to December 2003 were retrospectively identified. Complete clinical data including follow-up information and a detailed smoking history were obtained either by exhaustive electronic or manual query of clinical databases or by postal or personal communication with the patients, their families and at least two treating physicians. This review led to the exclusion of 29 cases due to incomplete clinical records (19 cases), prior treatment with neoadjuvant chemotherapy (two cases) or because the metastatic origin of the lung tumour could not be ruled out (eight cases). The study cohort therefore included a total of 188 chemonaive patients with primary lung AC, for which formol-fixed, paraffin-embedded tumour samples were available. According to the World Health Organisation definition [21] , a patient was considered an ES if she or he admitted to having smoked at least 100 cigarettes in his or her life, whereas patients who denied any active tobacco exposure or had smoked <100 cigarettes in their life were defined as NS. The study was carried out according to the national legal regulations.
immunohistochemistry
Whole sections were used for ERCC1 immunostaining, as in the IALT-Bio study [15] . Immunostaining for RPA and XPF was done on tissue microarray (TMA) slides. The TMA construction procedure has been previously described [22] .
Immunostaining was carried out using standard procedures following the Vectastain Elite ABC kit instructions. To enhance epitope exposure, deparaffinised slides were heated at 98°C in 10 mmol/l citrate buffer at pH 6 for 30 min. After blockade of endogenous peroxidases and nonspecific sites, slides were incubated with the primary antibody at 4°C overnight (ERCC1 antibody, clone 8F1, dilution 1 : 400 and RPA antibody, clone 9H8, dilution 1 : 200; Lab Vision, Fremont, CA; XPF antibody, clone SMP228, dilution 1 : 400; Abcam, Cambridge, UK,). The chromogen used to localise the antigen was NovaRED (Vector). Slides were counterstained with Mayer's haematoxylin. As a negative control, the staining procedure was carried out by omitting the primary antibody.
immunohistochemical evaluation
The whole sections were evaluated in at least five fields by one observer by light microscopy at ·100, ·200 and ·400 magnifications. The immunostained TMA slides were scanned (VM3 virtual scanner, Siemens, Germany) and registered as electronic archives of high-resolution and high-quality images, thus enabling the study of an identical image for each of the three spots by two independent readers at various magnifications.
As ERCC1, RPA and XPF were ubiquitously expressed in normal cells, the stromal or lung cells in tumour samples were carefully examined for the expression of each protein. Cases without any reactivity in stromal or lung cells were excluded from the analysis. Only nuclear staining of ERCC1, RPA and XPF was validated for the analysis.
The H-score was used for scoring ERCC1 immunostaining in the IALTBio study [15] . In order to evaluate semi-quantitatively the staining for each marker in a homogenous and comparable manner, the H-score method was also used for RPA and XPF. Briefly, the percentage of stained tumour cells (assigning a score of 0, 0.1, 0.5 or 1 for 0%, 1%-9%, 10%-49% or ‡50% of stained cancer cells, respectively) and the intensity of staining (scored 0 for the absence of staining to 3 for strong staining) were recorded. The H-score was calculated as the product of the percentage and intensity scores. Consequently, there were nine possible results for the H-score, on a scale of 0 (absence of stained cancer cells) to 3 (strong staining in at least half of the cancer cells).
statistical analysis
Differences between subgroups were assessed using Fisher's exact test or the Mann-Whitney U test. The Kendall tau statistic was used to measure the correlation between immunohistochemical variables. In order to be analysed as a dependent variable in the logistic regression models, the Hscores for each protein were dichotomised into low and high subgroups using the median as a cut-off point. The logistic regression models were developed with the smoking status and characteristics linked to the smoking status as exposure variables. Multivariate analysis of overall survival (OS) was carried out to examine whether protein expression was prognostic after adjustment for clinical and pathological variables in Cox proportional hazard models. All tests were two sided, and a P value of <0.05 was considered statistically significant. Among the 188 validated cases, 125 (66%) had a value for each protein (160, 138 and 174 cases were assessable for ERCC1, RPA and XPF, respectively) and were included in the analysis. The characteristics of the 125 included patients are shown in Table 1 . Patients who were included in the study and the 63 patients who were excluded were comparable in terms of demographic, clinical and histological characteristics.
The median age at diagnosis of the included patients was 63 years (interquartile range 54-72). Patients were well balanced between male and female (62 of 63). NS were more frequently women (28 of 30 or 93%) and older (median age 71.5 years, interquartile range 62-76) compared with ES (60 of 95 or 63%, P < 0.001; median age 60, interquartile range 53.5-70, P = 0.004). The tumours in NS exhibited BAC features more frequently (P = 0.03) (10 of 33 or 30%) compared with ES (14 of 95 or 15%). The median H-score was 2 (interquartile range 1-2) for both RPA and XPF, while it was 1 (interquartile range 0.2-2) for ERCC1. Representative examples of cases with strong positive and negative staining for each protein are provided in Figure 1 . There was a correlation between ERCC1 and XPF (tau = 0.24, P = 0.001). No correlation was observed between ERCC1 and RPA (tau = 0.11, P = 0.11).
univariate analysis of ERCC1, RPA and XPF protein expression according to smoking status
The median and interquartile range of the H-scores for ERCC1, RPA and XPF according to the smoking status are shown in Figure 2 and Table 2 . Using the Mann-Whitney U test, the ERCC1 H-scores were higher (P = 0.004) in NS (median 2, interquartile range 1-3) compared with ES (median 1, interquartile range 0.2-2). The same comparison showed that XPF was expressed at higher levels (P = 0.003) in NS (median 2, interquartile range 2-3) compared with ES (median 2, interquartile range 1-2). There was no difference in RPA expression between NS (median 2, interquartile range 1-2.75) and ES (median 2, interquartile range 1-2, P = 0.40).
The medians were used to distinguish high (positive) and low (negative) expression for each protein. The number of positive cases was 53 (or 42%), 78 (or 62%) and 86 (or 69%) for ERCC1, RPA and XPF, respectively. The proportions of positive cases were higher in NS for both ERCC1 (19 of 30 or 63%) and XPF (14 of 30 or 46%) compared with ES (ERCC1, 34 of 95 or 36%, P = 0.01; XPF, 8 of 95 or 8%, P < 0.0001). There was no difference for RPA (P = 0.40).
multivariate logistic regression analysis of ERCC1, RPA and XPA proteins
The logistic regression method was used to determine whether the dichotomised levels of ERCC1, RPA and XPF expression into subgroups of low and high expressers were explained by the smoking status after adjustment for clinical or pathological variables linked to the smoking status, including sex, age at diagnosis and the presence of BAC features ( Table 3 ). The smoking status was predictive of the ERCC1 level [odds ratio (OR) 2.5, 95% confidence interval (CI) 1.03-6.2, P = 0.04] after inclusion of age and BAC features. Identical results were noted when age was classified into subgroups: <55, 55-64 and >64 as in the IALT-Bio study. The smoking status was not predictive of the ERCC1 level when sex was included in the model. The smoking status was predictive of both RPA (OR 6.7, 95% CI 1.5-33.3) and XPF levels (OR 12.5, 95% CI 2.9-50) after adjusting for age, sex and BAC features.
overall survival
The median follow-up of the whole cohort was 54 months (range 1-189 months). In the study population, 43 deaths, whatever the cause, had been observed. Median OS was 94 months. Three-and 5-year cumulative OS was 77% and 67%, respectively.
After verification of the validity of the proportional hazards assumption, the effect of all clinical and pathological variables including age, sex, smoking status, pTNM (pathological In this model, ERCC1 positivity was not predictive of OS (HR 0.67, 95% CI 0.33-1.38, P = 0.28). Neither RPA nor XPF expression scores were predictive of OS (P > 0.45 for each variable).
The interaction test between ERCC1 and adjuvant chemotherapy was not significant. Only six patients with ERCC1-positive tumours had received adjuvant chemotherapy. In the subgroup of 111 patients, who had not received adjuvant chemotherapy, age (HR 1.06, 95% CI 1.02-1.11, P = 0.002) and pTNM (HR 1.67, 95% CI 1.19-2.34, P = 0.003), but not ERCC1 positivity (HR 0.55, 95% CI 0.25-1.16, P = 0.12), were significant predictors of OS.
discussion
Accumulating evidence points to numerous differences in genetic and epigenetic changes in lung cancer cells between ES and NS [2, [6] [7] [8] . Until now, no relationship has been shown for NER protein expression in lung cancer cells according to the smoking status. In the IALT-Bio study, which included 761 patients, no smoking data were recorded [15] . In that study, ERCC1 expression was found to be independently related to age and the histological type. In the study by Zheng et al. [20] , there were only 11 (6%) NS, a number that was too small to determine whether ERCC1 expression could be associated with the smoking status. To our knowledge, our study is the first to report the differential expression of ERCC1 and its NER partners RPA and XPF in NS compared with ES, using samples from patients with lung AC, who were consecutively treated by surgery at the same centre and whose smoking history was recorded by cross validating the clinical records. It should be noted that the relatively small number of NS in our cohort (30 of 125 or 24%) is consistent with epidemiological data on lung AC in France [23] . All together, our data indicate that the NER proteins ERCC1, RPA and XPF are differentially expressed according to the smoking status. The NER protein levels were generally higher in NS compared with ES, although a larger cohort and possibly the design of a case-control study are needed for a more precise evaluation of these differences.
We found that ERCC1 was higher in NS compared with ES both in univariate and multivariate analyses after controlling for age and the presence of BAC features-two characteristics which were associated with the smoking status. However, ERCC1 was not associated with the smoking status, when sex was included in the model. The data may indicate that never smoking status was not an independent predictor of ERCC1 after controlling for sex, which was itself strongly associated with ERCC1 in univariate but not in multivariate analysis, a finding previously reported in the IALT-Bio cohort [15] . We cannot rule out that NS status is not an independent predictor of ERCC1 expression, although NS status was the only variable marginally associated with ERCC1 (P = 0.09) in the multivariate model including sex. However, most NS were women, which limits the ability of the multivariate modeling to properly adjust for a confounding effect of sex. Indeed, by removing sex from the analysis, we found that NS status predicted ERCC1 expression.
Smoking status and BAC features were independent predictors of RPA expression by multivariate but not by univariate analysis. While never smoking status increased the likelihood of high RPA expression, presence of BAC features decreased it. The higher proportion of tumours with BAC features in NS confounded the relationship of never smoking status with RPA in the univariate analysis.
XPF was strongly associated with the smoking status both in univariate and multivariate analyses.
The fact that NS status was associated with higher NER protein levels suggests that tumour cell changes common to NS may be responsible for the differential modulation of NER gene expression. At present, little is known about the regulatory mechanisms governing the expression of ERCC1 and other NER proteins. A known level of regulation is the reciprocal down-regulation of protein expression between ERCC1 and XPF. Mouse knockout experiments have shown that a decrease in ERCC1 protein levels induces degradation of its heterodimeric partner XPF and reciprocally [24] . The correlation between ERCC1 and XPF reported in this study is consistent with this reciprocal relationship. It is not known whether down-regulation of protein levels affects primarily one of the two partners, ERCC1 and XPF, or both. Regarding transcriptional regulation, it has been reported that mutant H-Ras or exposure to epidermal growth factor modulates ERCC1 messenger RNA levels [25, 26] . However, these findings need to be confirmed and may depend on the cellular context. They point to the possible involvement of the RAS or epidermal growth factor receptor (EGFR) pathways, which are differentially altered in ES and NS.
Recent reports have established the predictive and prognostic value of ERCC1 expression in tumour cells in resected NSCLC [15, 19, 20] . Here, we report that the interaction term between ERCC1 and chemotherapy was not significantly associated with OS. However, only 14 patients 
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were treated with adjuvant chemotherapy in this cohort. In the left to observation arm (n = 111), the HR associated with ERCC1 positivity (HR 0.55, 95% CI 0.25-1.16, P = 0.12) was consistent with that reported in the IALT-Bio study (HR 0.66, 95% CI 0.49-0.90, P = 0.009) given the lower statistical power in the present study.
As there was a correlation between ERCC1 and XPF levels, it would be useful to determine whether XPF is predictive of a beneficial response to adjuvant chemotherapy as previously demonstrated for ERCC1. Such study is currently in progress using the IALT-Bio cohort.
NS with advanced stage NSCLC may benefit from treatment with EGFR inhibitors [27, 28] . At present, there is no evidence that EGFR inhibitors could improve the prognosis of patients with resected NSCLC. However, ERCC1 may be used as a predictor of a survival benefit from cisplatin-based adjuvant chemotherapy as shown in several studies [15, 29] . It is hoped that adjuvant chemotherapy may be tailored to the molecular profile of tumour cells. Our team is currently involved in a clinical trial to determine whether different therapeutic strategies can be implemented according to ERCC1 expression and EGFR mutations. The smoking status will be an important clinical characteristic in this trial. If confirmed by independent studies, the higher ERCC1 level in NS compared with ES is a finding that may reinforce the decision to treat NS patients with resected lung AC with an EGFR inhibitor instead of cisplatin-based adjuvant chemotherapy.
conclusion
The NER proteins ERRC1, RPA and XPF are differentially expressed according to the smoking status. ERCC1 and XPF are correlated and expressed at a higher level in NS compared with ES. Further studies are needed to confirm these results and to explain precisely the oncogenetic alterations that are associated with ERCC1 expression and the function of other NER proteins. 
